Stocks Screener

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Grifols SA ADR

GRFS
Current price
9.47 USD -0.21 USD (-2.17%)
Last closed 9.55 USD
ISIN US3984384087
Sector Healthcare
Industry Drug Manufacturers - General
Exchange NASDAQ
Capitalization 7 572 953 600 USD
Yield for 12 month -0.21 %
1Y
3Y
5Y
10Y
15Y
GRFS
21.11.2021 - 28.11.2021

Grifols, S.A. operates as a plasma therapeutic company in Spain, the United States, Canada, and internationally. The company provides immunoglobulin to treat immunodeficiencies; albumin used to restore circulatory volume and protein loss in pathophysiological conditions, such as liver cirrhosis, cardiocirculatory failure, trauma and severe burns; alpha-1 proteinase inhibitor, a plasma protein, used to treat a genetic disease known as alpha-1; factorVIII/von Willerbrand factor and factor IX, clotting factors for the treatment of hemophilia A and von Willebrand's disease, as well as hemophilia B; antithrombin III to treat hereditary antithrombin deficiency; Fostamatinib, a spleen tyrosine kinase inhibitor; combination of fibrinogen and enzyme thrombin that acts as a biological sealant to control surgical bleeding; and plasma exchange with albumin used to treat Alzheimer's disease. It markets diagnostic testing equipment, reagents, and other equipment; biological products; manufactures and sells plasma to third parties; and involves in research activities, as well as markets pharmaceutical products for hospital pharmacies. In addition, the company offers Yimmugo PID, an immunology drug; and Yimmugo ITP, a hematology drug. Further, it develops Xembify Pre-filled syringes, FlexBag, and Prolastin vials; Xembify Biweekly dosing, Prolastin-C, Fostamatinib2, and VISTASEAL which are in Phase IV development stage; Xembify, Albumin 20% and 5%, Fibrinogen, Trimodulin, Cytotec pregnancy, and AMBAR-Next in Phase III development stage; and AKST4290 that is in Phase II clinical development. Additionally, it offers recIG, Alpha-1 AT in non-cystic fibrosis bronchiectasis, ATIII, GIGA 2339, GIGA564, and OSIG. It has collaboration agreements with Canadian Blood Services for the processing of other plasma-derived products and with GIANT; and GigaGen to develop recombinant polyclonal immunoglobulin therapies. The company was founded in 1909 and is headquartered in Barcelona, Spain. Address: Avinguda de la Generalitat, 152, Barcelona, Spain, 08174

Check your investment idea

Find the best to beat the market
TSLA TSLA Tesla Motors
AAPL AAPL Apple
MSFT MSFT Microsoft

Analytics

WallStreet Target Price

10.67 USD

P/E ratio

36.5

Dividend Yield

Current Year

+7 025 709 155 USD

Last Year

+6 462 957 693 USD

Current Quarter

+1 937 519 784 USD

Last Quarter

+1 732 671 473 USD

Current Year

+2 475 527 703 USD

Last Year

+2 378 357 927 USD

Current Quarter

+661 621 184 USD

Last Quarter

+691 070 220 USD

Key Figures GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA 1 259 037 056 USD
Operating Margin TTM 20.06 %
PE Ratio 36.5
Return On Assets TTM 2.87 %
PEG Ratio 0.2481
Return On Equity TTM 2.71 %
Wall Street Target Price 10.67 USD
Revenue TTM 7 006 118 912 USD
Book Value 7.87 USD
Revenue Per Share TTM
Dividend Share
Quarterly Revenue Growth YOY 12.2 %
Dividend Yield
Gross Profit TTM 2 231 530 000 USD
Earnings per share 0.26 USD
Diluted Eps TTM 0.26 USD
Most Recent Quarter II 2024
Quarterly Earnings Growth YOY -66.7 %
Profit Margin 2.31 %

Dividend Analytics GRFS

Dividend growth over 5 years

Continuous growth

1 year

Payout Ratio 5 years average

50 %

Dividend History GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date 03.06.2021
Forward Annual Dividend Yield
Last Split Factor 2:1
Payout Ratio
Last Split Date 04.01.2016
Dividend Date 14.06.2021

Stock Valuation GRFS

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE 36.5
Forward PE 13.6986
Enterprise Value Revenue 2.1991
Price Sales TTM 1.0809
Enterprise Value EBITDA 10.5019
Price Book MRQ 1.1222

Financials GRFS

1 year
3 years
5 years
10 years
15 years
Results 2019 Dynamics
* The data for this period has not yet been published

Technical indicators GRFS

For 52 weeks

5.3 USD 12.15 USD
50 Day MA 8.85 USD
Shares Short Prior Month 4 569 543
200 Day MA 7.72 USD
Short Ratio 5.84
Shares Short 4 382 194
Short Percent 0.4 %